BioSpace

Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers

Eli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.

By BioSpace

1 min read
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights